GlassScriptPhysician profile
Jessica Van Mason
NPI 1225422280
$4,630.79
in general payments reported to CMS, 2019-2025
26 companies · $1,750 in 2025
The $1,750 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $270 · 2021: $530 · 2022: $596 · 2023: $406 · 2024: $915 · 2025: $1,750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.56 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $920.76 | 2021-2025 | Dupixent |
| Genzyme Corporation | $558.80 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $514.74 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Astrazeneca Pharmaceuticals LP | $436.74 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $426.21 | 2019-2025 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $303.21 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $239.33 | 2019-2025 | Andembry, Hizentra |
| Genentech USA, INC. | $188.87 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $155.34 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $144.61 | 2025 | |
| Pfizer INC. | $136.69 | 2020-2025 | |
| Amgen INC. | $106.36 | 2024-2025 | Tezspire |
| Optinose US, INC. | $60.80 | 2024-2025 | |
| Pharming Healthcare, INC. | $59.40 | 2022-2025 | Ruconest |
| Cycle Pharmaceuticals INC | $58.87 | 2024-2025 | Sajazir |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.56 | 2021 | |
| Octapharma USA, INC. | $47.00 | 2024-2025 | Cutaquig |
| Aimmune Therapeutics, INC. | $46.41 | 2022-2023 | |
| Covis Pharma Gmbh | $28.88 | 2021 | |
| X4 Pharmaceuticals, INC. | $28.79 | 2024 | Xolremdi |
| Ionis Pharmaceuticals, INC. | $23.62 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $20.48 | 2024 | Ryaltris |
| Abbvie INC. | $19.82 | 2024 | |
| Biocryst US Sales Co., LLC | $19.72 | 2025 | Orladeyo |
| Kaleo, INC. | $19.18 | 2023 | Auvi-Q |
| Philips North America LLC | $15.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Van Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.